Immunovant Inc is a clinical-stage biopharmaceutical company pioneering research into autoimmune diseases. Operating globally from the US, Immunovant Inc focuses on developing innovative therapies for patients with debilitating diseases.
Situated within the biotech sector, Immunovant primarily dedicates its resources to discovering innovative, patient-centric treatments. The company is currently leading research for IMVT-1402, a novel therapy for autoimmune conditions. Although independent, Immunovant Inc benefits from the guidance of Roivant Sciences, a larger healthcare sector organisation.
Diversify your virtual portfolio by monitoring the IMVT share price on eToro.